MTOR and mature T-cell and NK-cell non-Hodgkin lymphoma: Studies of other agents such as lenalidomide, nucleoside analogs, proteasome inhibitors, the mTOR inhibitor everolimus, and the JAK inhibitor ruxolitinib are also currently in clinical trials for PTCL [1–3, 68–70].